Search arXiv⌕ Search
Home/Archive/arXiv

arXiv · 2610.17396

Model-Based Cortisol Replacement Strategies for Patients With Adrenal Insufficiency

Nayana Saha·Renuka Joshi·Vittal Srinivasan·Stanislaw H. Zak·Cary N. Mariash
View original source ↗Read source document ↗Export metadata ↓

Abstract

Cortisol is an essential hormone secreted by the adrenal glands. Abnormally low level of cortisol is referred to as adrenal insufficiency. This paper focuses on devising treatment strategies for patients suffering from adrenal insufficiency using a model-based approach. Two conditions of adrenal insufficiency are analysed. They are hypothalamic-pituitary (HP) and adrenal gland disorders. The hypothalamus, pituitary, and adrenal glands constitute the hypothalamus-pituitary-adrenal (HPA) axis, which regulates stress and maintains physiological homeostasis through cortisol secretion. A comparative analysis of the existing mathematical models of the HPA axis is conducted. Based on this analysis, a novel model of the HPA axis is proposed that incorporates endogenous circadian rhythm. This proposed model is used to design effective cortisol replacement strategies. In addition, hydrocortisone replacement therapies are proposed and validated with clinical data from the literature. The results presented in this paper are applicable to patient-specific treatment strategies for individuals with adrenal insufficiency.

Explore related subjects

q-bio.OTcs.SYeess.SY

Keep this discovery

Explore connections, maps & timelines

BibTeXRIS

Nayana Saha, Renuka Joshi, Vittal Srinivasan, Stanislaw H. Zak, Cary N. Mariash. 2026-10-12. Model-Based Cortisol Replacement Strategies for Patients With Adrenal Insufficiency. https://arxiv.org/abs/2610.17396

Cite the original work for its findings. Save a collection to share your selection of sources.

KEEP EXPLORING

Related papers

arXiv2026

Current validation practice undermines surgical AI development

Surgical data science (SDS) is rapidly advancing, yet clinical adoption of artificial intelligence (AI) in surgery remains limited, with inadequate validation as an important contributing factor. Existing validation practices often neglect the temporal and hierarchical structure of intraoperative videos, yielding misleading or clinically irrelevant results. We introduce a comprehensive catalogue of validation pitfalls in AI-based surgical video analysis, derived from a multi-stage Delphi process with 92 international experts. Pitfalls span three categories: (1) data, (2) metric selection/configuration, and (3) aggregation and reporting. A systematic review of surgical AI papers reveals that these pitfalls are widespread. Experiments on surgical video datasets show that ignoring temporal and hierarchical data structures can understate uncertainty, obscure critical failure modes, and alter algorithm rankings. To address these shortcomings, we provide consensus-based best practices compiled. Together, this work provides an evidence-based framework for rigorous validation of surgical video analysis algorithms, guiding benchmarking, reporting, regulatory review, and clinical translation.

q-bio.OT↗
arXiv2026

Cancer genomics, targeted therapy to precision oncology: the treatment paradigm is a holistic approach to cancer therapeutics

Cancer is a fatal genetic disease involving unregulated cell growth and proliferation. Cellular behaviors such as growth, proliferation, survival, or death rely upon the ability of cells to communicate with the surrounding system; therefore, effective targeting of dysregulated signaling pathways involving growth factors, regulatory proteins, cell adhesion molecules, and immune system molecules is critical to cancer therapy. They are mainly driven by alterations in tumor suppressor genes and oncogenes that may vary among different cancer types. Importantly, patients with the same cancer type respond differently to available cancer treatments, likely due to tumor-specific DNA, RNA, and proteins, indicating the need for patient-specific treatment options. Precision oncology has evolved as a form of cancer therapy focused on genetic and molecular profiling of tumors to identify specific molecular alterations involved in carcinogenesis for tailored individualized cancer treatment. This article aims to briefly explain the foundations and frontiers of precision oncology, highlighting the cutting-edge innovations in tools and techniques associated with it to assess its scope and importance in achieving efficacious cancer treatment over time.

q-bio.OT↗
arXiv2026

A mechanistic interpretation of mutation risk across biological scales

The allometry of cancer risk in mammals is scale-specific, as the inter-specific, intra-specific, and inter-organ patterns in cancer risk scaling are distinct from each other. While cancer risk barely changes with increasing body sizes across species, larger conspecifics are known to be at a higher risk of cancer. Cancer risk trends with age and lifespan have likewise been documented in humans and other species. Nevertheless, mammals broadly share developmental features, and the twin processes of cell division and differentiation are central to developmental dynamics. In this study, we suppose that a better understanding of these processes across biological scales could lead to a clearer understanding of cancer risk allometries. We develop an agent-based model in which a cell compartment grows from one cell to a target size. We assess how developmental dynamics scale with compartment size and influence mutation accumulation. Our data identify specific regions of the parameter space where the accumulation of neutral mutations increases with cell number, while providing a mechanistic explanation for such behavior. The accumulation of non-neutral mutations reveals an interesting antagonism in cell fitness between mutation and differentiation, which could change the viability of a given developmental strategy. Our model is able to produce a wide range of trends in cancer risk allometries in different parts of its parameter space, reflecting the observed heterogeneity across biological scales. Our results provide a theoretical framework that allows us to elucidate the conditions of mutation-differentiation balance under which having more cells does lead to higher cancer risk, and importantly, the conditions under which it does not.

q-bio.OT↗